| DRAVPc041 |
Avdoralimab |
Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection). |
COVID-19 |
402425685 |
| DRAVPc042 |
Meplazumab |
Meplazumab is an anti-CD147 antibody, which is a recepor on host cells for viruses such as SARS-CoV2. Meplazumab's inhibition of CD147 binding to the spike proteins of viruses is thought to inhibit their entry.It is investigated as an add-on therapy in patients with COVID-19 pneumonia. |
COVID-19 |
405560467 |
| DRAVPc043 |
Regdanvimab |
Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate. Regdanvimab is indicated in the EU for the treatment of adult patients with COVID-19 who do not require supplemental oxygen and who are at risk of progressing to severe COVID-19. |
COVID-19 |
434321767 |
| DRAVPc044 |
PUL-042(PAM2CSK4 acetate) |
Pam2 is a synthetic lipopeptide which acts as an agonist at TLR2 and TLR6. Actions at these receptors suggest that Pam2 has potential antiviral properties. |
COVID-19 |
165411979 |
| DRAVPc045 |
Aviptadil |
Aviptadil is a synthetic form of vasoactive intestinal polypeptide (VIP), with potential anti-cytokine, anti-inflammatory, and immune-regulatory activities. Upon administration, aviptadil mimics endogenous VIP. In the lungs, aviptadil may prevent N-Methyl-D-aspartic acid (NMDA)-induced caspase-3 activation, inhibits the production of certain pro-inflammatory mediators, such as interleukin-6 (IL-6) and tumor-necrosis factor-alpha (TNFa), and may protect the lungs against a cytokine storm and inflammation. As cytokines cause the air sacs of the lungs to fill with water, making the sacs impermeable to oxygen, aviptadil may protect against pulmonary edema, and restores the barrier function at the endothelial/alveolar interface. This may improve blood oxygenation, respiratory distress, and prevent lung injury. VIP is a naturally synthesized peptide hormone that is highly concentrated in the lungs. |
COVID-19 |
16132300 |
| DRAVPc046 |
Solnatide |
Solnatide has been used in trials studying the treatment of Acute Lung Injury. |
COVID-19 caused Acute Lung Injury |
91864495 |
| DRAVPc047 |
Metenkefalin |
Metenkefalin is a synthetic form of the naturally occurring, endogenous opioid peptide, metenkephalin, and agonist of the zeta- and delta-opioid receptor and, to a lesser extent the mu-opioid receptor, with potential analgesic, neuromodulatory, immunomodulatory, anti-inflammatory, antinociceptive/analgesic, antidepressant, and gastrointestinal (GI) motility modulating activities. It is an investigational endogenous opioid being studied for the treatment of COVID-19. Metenkefalin, along with tridecactide, are under investigation as an immunomodulatory therapy for moderate to severe COVID-19. |
COVID-19 |
443363 |
| DRAVPc048 |
Hepalatide |
Hepalatide is used for the treatment of chronic hepatitis B virus infection. |
Chronic HBV infection |
438788936 |
| DRAVPc049 |
Flufirvitide-3(free c-terminal acid) |
Flufirvitide-3 is used for the treatment of influenza virus infection. |
Influenza virus infection |
134812039 |
| DRAVPc050 |
Adaptavir(Dapta) |
Adaptavir is under clinical for the treatment of HIV infection. |
HIV infection |
184644 |
To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.